Inflammatory Bowel Disease (IBD) Adjunctive Support Protocol
Primary Stack
Core supplements with strongest evidencePotent anti-inflammatory that may help maintain remission and reduce disease activity in IBD
May help restore gut microbiome balance and maintain remission, particularly in ulcerative colitis
Supporting Stack
Additional supplements for enhanced resultsDeficiency very common in IBD and associated with disease activity; supplementation may improve outcomes
Supporting Studies (1)
Anti-inflammatory effects may help reduce colonic inflammation in IBD
Supporting Studies (1)
Antioxidant and anti-inflammatory that may reduce disease activity and oxidative stress
Supporting Studies (1)
Primary fuel for intestinal cells; may support gut barrier repair
Supporting Studies (1)
Anti-inflammatory herb that inhibits 5-lipoxygenase; studied for IBD
Supporting Studies (1)
Addresses iron-deficiency anemia common in IBD due to blood loss and malabsorption
Supporting Studies (1)
Deficiency common in IBD; supports wound healing and gut barrier function
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis - chronic conditions causing inflammation of the digestive tract. IBD involves immune system dysfunction, with the body attacking the gut lining. Symptoms include diarrhea (often bloody), abdominal pain, fatigue, and weight loss. IBD alternates between flares and remission. While medication is the foundation of treatment, certain supplements may help reduce inflammation, support gut healing, and maintain remission.
CRITICAL: IBD is a serious medical condition requiring gastroenterologist care. Standard treatments include aminosalicylates, corticosteroids, immunomodulators, and biologics. These supplements are ADJUNCTIVE - they support but don't replace medical treatment. Always inform your GI doctor about supplements, as some may interact with medications or affect disease monitoring.
* Curcumin (from turmeric) is one of the most promising supplements for IBD. It has powerful anti-inflammatory effects through multiple pathways. Clinical trials show it helps maintain remission in ulcerative colitis and may reduce disease activity. Use a bioavailable form for better absorption.
* Probiotics help restore the disrupted gut microbiome in IBD. The high-potency VSL#3 formulation has the most evidence, particularly for ulcerative colitis and pouchitis. Probiotics are more established for ulcerative colitis than Crohn's disease.
* Vitamin D deficiency is very common in IBD (up to 60-75% of patients) and associated with more active disease. Vitamin D has immunomodulatory effects and maintaining adequate levels may help reduce flares and improve outcomes.
* Omega-3 Fatty Acids have anti-inflammatory effects, though evidence in IBD is mixed. They may provide modest benefit as part of a comprehensive approach.
* Resveratrol has antioxidant and anti-inflammatory properties. Early clinical trials in ulcerative colitis showed promising results in reducing disease activity.
* Glutamine is the primary fuel for intestinal cells. It supports gut barrier function and may help with healing, though clinical evidence in IBD is limited.
* Boswellia is an Ayurvedic herb with anti-inflammatory effects through 5-lipoxygenase inhibition. Some studies show benefit in Crohn's disease.
* Iron supplementation is often necessary in IBD due to iron-deficiency anemia from chronic blood loss and poor absorption. IV iron is often better tolerated and more effective than oral iron.
* Zinc deficiency is common in IBD and can impair wound healing. Supplementation may support gut barrier repair.
Expected timeline: Curcumin and anti-inflammatory herbs: 4-8 weeks for effects. Probiotics: 2-4 weeks to shift microbiome. Vitamin D: 8-12 weeks to optimize levels. Iron: 4-8 weeks to improve anemia. These supplements provide ongoing support alongside medical therapy.
Clinical Perspective
IBD comprises Crohn's disease (transmural inflammation, any GI location, skip lesions) and ulcerative colitis (mucosal inflammation, continuous from rectum). Pathophysiology: genetic susceptibility + environmental triggers + dysregulated immune response to gut microbiota. Montreal classification guides phenotyping. Goals: induce and maintain remission, achieve mucosal healing, prevent complications (strictures, fistulae, cancer). Treatment: aminosalicylates, corticosteroids, immunomodulators (thiopurines, methotrexate), biologics (anti-TNF, vedolizumab, ustekinumab), JAK inhibitors.
CRITICAL: IBD requires GI specialist management. Severe flares may need hospitalization. Screen for: malnutrition, osteoporosis, vitamin deficiencies (D, B12, folate, iron, zinc). Supplements are ADJUNCTIVE to standard therapy. Surgery may be needed for complications or refractory disease. Colorectal cancer surveillance required. Some supplements may interact with immunosuppressants.
* Curcumin (B-grade): NF-kB inhibitor; reduces TNF-alpha, IL-1, IL-6. Systematic review: curcumin as adjunct improves clinical and endoscopic outcomes in UC (PMID: 28426088). Meta-analysis confirms benefit (PMID: 30939239). 1-3g daily bioavailable form. Generally safe; may interact with anticoagulants. Less evidence for Crohn's.
* Probiotics (B-grade): Restore microbiome diversity, strengthen tight junctions, modulate immune response. Cochrane review: probiotics may help induce remission in UC when added to standard therapy (PMID: 28746088). VSL#3 most studied (PMID: 21226722). 10-450 billion CFU daily. More evidence for UC than Crohn's. E. coli Nissle 1917 also studied for UC maintenance.
* Vitamin D (B-grade): VDR in gut epithelium; affects barrier function, antimicrobial peptides, Th17/Treg balance. Deficiency in 30-75% of IBD patients. Systematic review: vitamin D deficiency associated with disease activity (PMID: 30179253). Target 40-60 ng/mL. 2000-5000 IU daily; higher if deficient.
* Omega-3 Fatty Acids (C-grade): Reduce inflammatory eicosanoids. Cochrane review: omega-3s don't clearly maintain remission in IBD (PMID: 24189255). May have modest benefit. 2-4g EPA+DHA daily.
* Resveratrol (B-grade): Antioxidant; modulates inflammatory pathways. Clinical trial: reduced disease activity in UC patients (PMID: 28494760). 200-500mg daily. Limited but promising data.
* Glutamine (C-grade): Enterocyte fuel; supports gut barrier. Review: may help in IBD but clinical data limited (PMID: 17307102). 10-20g daily. More theoretical than proven in IBD.
* Boswellia (C-grade): Boswellic acids inhibit 5-LOX. Clinical trial: comparable to mesalazine for Crohn's (PMID: 11416878). 300-400mg TID. Limited high-quality data.
* Iron (A-grade): Iron-deficiency anemia affects 30-90% of IBD patients. ECCO guidelines: iron supplementation indicated for iron deficiency (PMID: 26762197). IV iron preferred in active disease, malabsorption, oral intolerance. Target ferritin >100 ng/mL (>300 with inflammation).
* Zinc (C-grade): Deficiency from malabsorption and losses. Review: zinc important for gut barrier, wound healing in IBD (PMID: 26176050). 25-50mg daily. Monitor copper long-term.
Biomarker targets: Fecal calprotectin (<150-250 mcg/g remission), CRP, albumin, hemoglobin, ferritin, vitamin D (>40 ng/mL), zinc, B12, folate, endoscopic healing (Mayo score 0-1 for UC, SES-CD for Crohn's).
Protocol notes: Aminosalicylates are first-line for mild-moderate UC. Step-up therapy for inadequate response. Early biologic therapy for high-risk disease (young age, extensive disease, perianal, deep ulcers). Corticosteroids for acute flares only - not maintenance. Screen for C. diff in flares. Consider enteral nutrition for active Crohn's (especially pediatric). Address smoking - harmful in Crohn's (protective in UC but don't recommend). Bone health: vitamin D, calcium, DXA screening. Surveillance colonoscopy starting 8-10 years after diagnosis. Vaccinations (especially before biologics). Mental health support. Consider low-FODMAP trial for functional symptoms overlapping IBD. Diet: no single diet works for all; Mediterranean-style generally recommended. Avoid NSAIDs (can trigger flares).